Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Venous Leg Ulcers (Crural ulcer) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Venous Leg Ulcers (Crural ulcer) Overview | 8 | 1 |
| Venous Leg Ulcers (Crural ulcer) Therapeutics under Development by Companies | 9 | 1 |
| Venous Leg Ulcers (Crural ulcer) Pipeline Products Glance | 10 | 4 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Venous Leg Ulcers (Crural ulcer) Products under Development by Companies | 14 | 1 |
| Venous Leg Ulcers (Crural ulcer) Companies Involved in Therapeutics Development | 15 | 11 |
| Adocia | 15 | 1 |
| CardioVascular BioTherapeutics, Inc. | 16 | 1 |
| CytoTools AG | 17 | 1 |
| FirstString Research, Inc. | 18 | 1 |
| MacroCure Ltd. | 19 | 1 |
| MediWound Ltd. | 20 | 1 |
| NovaLead Pharma Pvt. Ltd. | 21 | 1 |
| Pergamum AB | 22 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 23 | 1 |
| Stratatech Corporation | 24 | 1 |
| Tissue Therapies Limited | 25 | 1 |
| Venous Leg Ulcers (Crural ulcer) Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 25 |
| Biochaperone PDGF-BB Drug Profile | 35 | 2 |
| Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer Drug Profile | 37 | 2 |
| Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers Drug Profile | 39 | 1 |
| CL-05 Drug Profile | 40 | 3 |
| CODA-001 Drug Profile | 43 | 2 |
| CureXcell Drug Profile | 45 | 1 |
| CVBT-141B Drug Profile | 46 | 2 |
| EscharEx Drug Profile | 48 | 2 |
| Granexin Drug Profile | 50 | 2 |
| LL-37 Drug Profile | 52 | 2 |
| NLP-328 Drug Profile | 54 | 1 |
| PAC-G Drug Profile | 55 | 1 |
| RGN-137 Drug Profile | 56 | 2 |
| Stathmin-1 Drug Profile | 58 | 1 |
| VF-001 Drug Profile | 59 | 1 |
| Venous Leg Ulcers (Crural ulcer) Dormant Projects | 60 | 1 |
| Venous Leg Ulcers (Crural ulcer) Discontinued Products | 61 | 1 |
| Venous Leg Ulcers (Crural ulcer) Product Development Milestones | 62 | 8 |
| Featured News &Press Releases | 62 | 1 |
| May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial | 62 | 1 |
| Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update | 62 | 1 |
| Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers | 63 | 1 |
| Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment | 64 | 1 |
| Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results | 64 | 1 |
| Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications | 65 | 1 |
| May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication | 66 | 1 |
| Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers | 66 | 1 |
| Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers | 67 | 1 |
| Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers | 68 | 1 |
| Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds | 68 | 1 |
| Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results | 68 | 1 |
| Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |